Correcting calculation and data errors reveals that the original conclusions were incorrect in “The best drug supplement for obesity treatment: a systematic review and network meta-analysis”

Yu, Xiaoxin; Capers, Patrice L.; Zoh, Roger S.; Allison, David B.

doi:10.1186/s13098-023-01134-6

Table 1 Re-extracted information on mean age and treatment alongside data reported in the Salari et al. paper

From: Correcting calculation and data errors reveals that the original conclusions were incorrect in “The best drug supplement for obesity treatment: a systematic review and network meta-analysis”

				Age (y; Salari Paper)		Age (y; New Results^a)
Study	Year	Groups (Salari Paper)	Groups (New Results^a)	Mean	SD	Mean	SD
Apovian [9]	2013	Placebo	Placebo	44.4	11.4	44.4	11.4
		Naltrexone + bupropion	32 mg/day naltrexone SR + 360 mg/day bupropion SR (NB32)	44.3	11.2	44.3	11.2
Aronne [10]	2010	Placebo	Placebo	42	11	42	11
		Pramlintide	Pramlintide (120 µg sc)	42	11	42	11
			Pramlintide (120 µg sc t.i.d.) + sibutramine (10 mg oral q.a.m.)			43	11
			Pramlintide (120 µg sc t.i.d.) + phentermine (37.5 mg oral q.a.m.)			39	10
Davies [7]	2015	Placebo	Placebo	54.7	9.8	54.7	9.8
		Liraglutide 0.3 mg	Liraglutide 3.0 mg			55	10.8
		Liraglutide 1.8 mg	Liraglutide 1.8 mg			54.9	10.7
Fidler [11]	2011	Placebo	Placebo	43.7	11.8	43.7	11.8
		Lorcaserin 10 mg BID	Lorcaserin 10 mg BID	43.8	11.8	43.8	11.8
		Lorcaserin 10 mg QD	Lorcaserin 10 mg QD	43.8	11.7	43.8	11.7
Gadde [12]	2011	Placebo	Placebo	51.2	10.25	51.2	10.25
		Phentermine 7.5 mg + topiramate 46.0 mg	Phentermine 7.5 mg + topiramate 46.0 mg	51.1	10.43	51.1	10.43
		Phentermine 15.0 mg + topiramate 92.0 mg	Phentermine 15.0 mg + topiramate 92.0 mg	51	10.65	51	10.65
Greenway [8]	2010	Placebo	Placebo	43.7	11.1	43.7	11.1
		Naltrexone + bupropion 16.0 mg	Naltrexone16.0 mg + bupropion	44.4	11.3	44.4	11.3
		Naltrexone + bupropion 32.0 mg	Naltrexone32.0 mg + bupropion	44.4	11.1	44.4	11.1
Le Roux [13]	2017	Placebo	Placebo	47.3	11.8	47.3	11.8
		Liraglutide	Liraglutide 3.0 mg	47.5	11.7	47.5	11.7
Lu [14]	2018	Placebo	Placebo	37	10	37	10
		Lorcaserin	Lorcaserin 10.0 mg	34.7	9	34.7	9
O’Neil [15]	2012	Placebo	Placebo	53.2	8.3	52	9.3
		Orlistat 120.0 mg BID	Lorcaserin 10 mg BID	53.9	8.1	53.2	8.3
		Orlistat 120.0 mg QD	Lorcaserin 10 mg QD	53.5	7.4	53.1	8
Pi-Sunyer [16]	2015	Placebo	Placebo	45.2	12.1	45	12
		Liraglutide	Liraglutide 3.0 mg QD	45	12	45.2	12.1
Smith [17]	2010	Placebo	Placebo	44.4	0.3	44.4	0.3
		Lorcaserin	Lorcaserin 10.0 mg	43.8	0.3	43.8	0.3

Abbreviations: BID, twice a day; q.a.m., every morning; QD, every day; sc, subcutaneous; t.i.d., three times a day
The difference between our extraction and original study used underlining
a: “New” results are from our data extraction from the original studies. Underlining denotes discrepant values

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com

Diabetology & Metabolic Syndrome

Contact us